Importantly, immunotherapy employing this strategy specifically aims at the earliest possible pathogenic form of tau rather than the physiological trans form of pT231-tau with normal functions in AD (Kondo et al., 2015). The gene discussed is MAPT; the disease is Alzheimer disease.